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A commentary on
Novel fusion protein derived from vaso-
statin 30 and vasoinhibin II-14.1 potently
inhibits coronary endothelial cell prolif-
eration
by Vazquez Rodriguez G, Gonzalez C,
De Leon Rodriguez A. Mol Biotechnol
(2013) 54(3):920–9. doi:10.1007/ s12033-
012-9642-4
Prolactin and growth hormone are pro-
duced in the anterior pituitary gland and
secreted into the circulation to execute their
diverse physiological effects. They are also
produced at various extrapituitary sites.
Apart from the traditional, well-known
effects mediated by the full-length hor-
mones, they serve as the source for vasoin-
hibins, which are generated by proteolytic
cleavage of prolactin and growth hormone,
and also of placental lactogen (1, 2). Promi-
nent, name-giving biological effects of
vasoinhibins include inhibition of angio-
genesis, vasodilation, and vasopermeabil-
ity (1–3). As this set of vascular effects
is unique, and entirely different from the
characteristics of their precursors, vasoin-
hibins constitute a separate hormonal fam-
ily (1, 2). Apart from physiological func-
tions, vasoinhibins seem to be involved
in the pathogenesis of diabetic complica-
tions (4, 5), cancer (6, 7), and pregnancy-
associated diseases (8–10). At present,
approximately one and a half dozen pro-
teins have been ascribed to belong to the
vasoinhibin-family. Each of them differs
by precursor, the enzyme responsible for
proteolytic generation of the respective
vasoinhibin-isoform, and consequently by
amino acid sequence and molecular mass.
The generation of vasoinhibins has thor-
oughly been demonstrated in vitro, and
ongoing research has led to accumulating
information about their generation in vivo
and their pathophysiological role and clin-
ical significance in the aforementioned
diseases. However, as more information
surfaced, the need for a precise terminology
designating a specific vasoinhibin-isoform
under study rose in parallel. For example,
the term “16K PRL,” often used to describe
16 kDa-like prolactin-derived vasoinhib-
ins, does not discriminate between the
different vasoinhibin-isoforms present. Of
note, prolactin-derived vasoinhibins alone
include several proteins with <4 kDa dif-
ference in molecular mass between 14 and
18 kDa. This is of relevance as it remains
to be shown whether and to what extent
each of the different proteases contributes
to the physiological release of vasoinhib-
ins and how the generation of vasoin-
hibins is modified under disease condi-
tions. Accordingly, the total composition
of endogenous vasoinhibins in the circu-
lation or at the target-tissue level has yet
to be determined. To address the need
for a terminology with which it is possi-
ble to precisely differentiate between pro-
teins ascribed to the vasoinhibin-family,
Vazquez Rodriguez et al. proposed a clas-
sification according to precursor, prote-
olytic enzyme involved in the genera-
tion of the respective protein, its sequence
and theoretical molecular mass, consider-
ing a variety of 20 proteins derived from
prolactin, growth hormone, and placen-
tal lactogen (11). However, because of
the presence of important limitations in
understanding and a number of unresolved
issues, which are presently inherent to the
field, the proposed classification can only
be considered as premature. It remains
to be demonstrated if fragments derived
from growth hormone and placental lac-
togen are generated in vivo, exert antian-
giogenic effects and can consequently be
classified as vasoinhibins. Also, there is
neither understanding as to which dif-
ferences in molecular mass impact func-
tion of vasoinhibins nor is there any evi-
dence of a clinical relevance of vasoin-
hibins derived from growth hormone and
placental lactogen. Lastly, significant dif-
ferences in sequence, structure, and func-
tion of prolactin, growth hormone, and
placental lactogen exist between species
and naturally, the smallest fraction of the
total body of evidence derives from stud-
ies in humans. Accordingly, a sustainable
classification that provides orientation in
future research and in the clinical con-
text can only be proposed on the basis of
substantial information on the structure
and biological function or dysfunction of
vasoinhibins in human health and disease.
Further, a classification of hormones of
the vasoinhibin-family should be proposed
after being subject of a consensus confer-
ence of experts in the field. We suggest that
an appropriate occasion for this consen-
sus conference are the FASEB-Conferences
on “The Growth Hormone/Prolactin Fam-
ily in Biology and Disease,” during which
new evidence can be reviewed and the pos-
sibility of a sustainable classification of
hormones of the vasoinhibin-family can
be reevaluated. Until such agreement is
met, the field will benefit from the precise
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description of each vasoinhibin tested and
discovered.
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